Enlightenment Research’s Novavax NVAX Stock Holding History

Enlightenment Research’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,700	Closed	-$815K	–	184
2021 Q4	$815K	Buy	+5,700	New	+$979K	1.16%	22

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Enlightenment Research's NVAX Position: Q1 2022 in Review

Enlightenment Research sold out of Novavax (NVAX) in Q1 2022, closing a stake of 5,700 shares — an estimated $815K sold.

Enlightenment Research first reported a position in NVAX in Q4 2021 and held it in 1 quarter. The position peaked at $815K in Q4 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

Enlightenment Research reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
Enlightenment Research sold 5,700 Novavax shares in Q1 2022, an estimated $815K.
Enlightenment Research first reported a position in Novavax in Q4 2021 and held it in 1 quarter.
Enlightenment Research's Novavax position peaked at $815K in Q4 2021.
381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Enlightenment Research's 13F filing for Q1 2022, filed 13 May 2022.